Pathogenesis of HIV-1 protease inhibitor-associated partial lipodystrophy: An ultrastructural study

被引：0
|
作者：
Lloreta, J
Domingo, P
Pujol, RM
Baixeras, N
Matias-Guiu, X
Serrano, S
机构：
[1] Univ Pompeu Fabra, Barcelona, Spain
[2] Autonomous Univ Barcelona, Barcelona, Spain
[3] IMIM, IMAS, Hosp Mar, Barcelona, Spain
[4] Hosp Sant Pau, Barcelona, Spain
来源：
LABORATORY INVESTIGATION | 2001年 / 81卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1407
引用
收藏
页码：238A / 238A
页数：1
相关论文
共 50 条
  • [1] Pathogenesis of HIV-1 protease inhibitor-associated partial lipodystrophy: An ultrastructural study
    Lloreta, J
    Domingo, P
    Pujol, RM
    Baixeras, N
    Matias-Guiu, X
    Serrano, S
    MODERN PATHOLOGY, 2001, 14 (01) : 238A - 238A
  • [2] HIV-1 protease inhibitor-associated partial lipodystrophy: Clinicopathologic review of 14 cases
    Pujol, RM
    Domingo, P
    Xavier-Matias-Guiu
    Francia, E
    Sanbeat, MA
    Alomar, A
    Vazquez, G
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2000, 42 (02) : 193 - 198
  • [3] Subcutaneous adipocyte apoptosis in HIV-1 protease inhibitor-associated lipodystrophy
    Domingo, P
    Matias-Guiu, X
    Pujol, RM
    Francia, E
    Lagarda, E
    Sambeat, MA
    Vázquez, G
    AIDS, 1999, 13 (16) : 2261 - 2267
  • [4] Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance
    Carr, A
    Samaras, K
    Chisholm, DJ
    Cooper, DA
    LANCET, 1998, 351 (9119): : 1881 - 1883
  • [5] Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study
    Baldini, F
    Di Giambenedetto, S
    Cingolani, A
    Murri, R
    Ammassari, A
    De Luca, A
    AIDS, 2000, 14 (11) : 1660 - 1662
  • [6] Lipodystrophy associated with an HIV-protease inhibitor
    Carr, A
    Cooper, DA
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (18): : 1296 - 1296
  • [7] Protease inhibitor-associated lipodystrophy in HIV-seropositive men increases postprandial lipid oxidation.
    Ware, LJ
    Morlese, J
    Krueger, M
    Gazzard, B
    Jackson, AA
    Wootton, SA
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2000, 59 : 44A - 44A
  • [8] Insulin resistance in HIV protease inhibitor-associated diabetes
    Yarasheski, KE
    Tebas, P
    Sigmund, C
    Dagogo-Jack, S
    Bohrer, A
    Turk, J
    Halban, PA
    Cryer, PE
    Powderly, WG
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1999, 21 (03): : 209 - 216
  • [9] Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study
    Carr, A
    Samaras, K
    Thorisdottir, A
    Kaufmann, GR
    Chisholm, DJ
    Cooper, DA
    LANCET, 1999, 353 (9170): : 2093 - 2099
  • [10] Increasing prevalence of HIV-1 protease inhibitor-associated mutations correlates with long-term non-suppressive protease inhibitor treatment
    Kagan, R. M.
    Cheung, P. K.
    Huard, T. K.
    Lewinski, M. A.
    ANTIVIRAL RESEARCH, 2006, 71 (01) : 42 - 52
12345